| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PsO: psoriasis vulgaris, PsA: psoriatic arthritis, BMI: body mass index, MTX: methotrexate, PUVA: psoralen + ultraviolet A, 311 nm NB-UVB: 311-nanometer narrow-band ultraviolet B. Symmetrical arthritis: bilateral arthritis with a frequency of >50%. •Patients previously or currently treated with DMARDs, systemic therapy or full-body phototherapy were regarded as “moderate-to-severe” patients, whereas the others were considered to exhibit a “mild” disease course. |
Clinical Study
Higher Levels of Autoantibodies Targeting Mutated Citrullinated Vimentin in Patients with Psoriatic Arthritis Than in Patients with Psoriasis Vulgaris
Table 1
Basic demographic and clinical characteristics of psoriatic arthritis (PsA) and psoriasis (PsO) groups.